Clinical trials: Donor
Blood Donors
A Survey of Attitudes of Experienced Blood Donors
This study examines the effects of a web-based motivational interview on 1) internal motivation to donate blood; 2) donor autonomy, competence and relatedness; and 3) donation intention and behavior.
- Trial name
- NCT03102385
- Testing
- Motivational Interview, Knowledge Interview
- Where
- United States
- Volunteers
- 1,177 people
- Sponsor
- Ohio University
End Stage Renal Disease, Kidney Failure
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not…
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Trial name
- C1INHDGF (NCT02134314)
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cedars-Sinai Medical Center
Survival, Embryo Quality
Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage.
The survival rate (and embryo quality) of donor oocytes with two commercially available devices.
- Trial name
- NCT01952184
- Testing
- CBSvit HS device, Cryotop SC device
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00540995
- Testing
- busulfan, etoposide, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test the safety of specialized white cells from the donor at different doses. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT01758328
- Testing
- busulfan, melphalan, fludarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Electrolyte Imbalance, Kidney Transplant; Complications
The Comparison Between Ringer Lactate Solution and Normal Saline With Dextrose Water in Post-Operative Period of Kidney Transplantation
This is a randomized controlled pragmatic clinical trial. We aim to evaluate the effect of Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W) on the electrolyte abnormality of kidney…
- Trial name
- RINNOR (NCT06030609)
- Testing
- Ringer's Lactate Crystalloid Solutions, Normal saline
- Where
- Thailand
- Volunteers
- 159 people
- Sponsor
- King Chulalongkorn Memorial Hospital
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Brain Death
Organ Donor Tissue Oxygen Saturation as a Predictor of Number of Organs to Transplant Per Donor
The objective of this study is to quantify the association between tissue oxygen saturation (StO2) during the donor management phase of the Death by Neurological Criteria (DNC) organ donor and the number of organs transplanted…
- Trial name
- NCT01819116
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Kidney Transplant
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab. or 250mg/Cap.) in Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients
- Trial name
- NCT03794492
- Testing
- Mycophenolate mofetil 500mg Tab. or 250mg Cap., Tacrolimus, Methylprednisolone/prednisolone
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT).
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
- Trial name
- NCT03751709
- Testing
- Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Transplantation
Precise Cooler for Donor Heart Transport
The investigators are doing this study to compare approaches to cold storage of donor hearts during transportation. The adjustable temperature RYOBI cooler should allow precise temperature control while reducing environmental…
- Trial name
- NCT07354763
- Testing
- Organ transport using SherpaPak, Ryobi cooler for Organ Transport
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Relapsed Hematologic Malignancy
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the…
- Trial name
- Haplo-CIK (NCT03821519)
- Testing
- donor-derived CIK cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Wound Healing, Wound Infection
Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh
This study aims to compare the effectiveness of two wound dressings, Acticoat Absorbent (AA) and BCT Antimicrobial (BCT) on Split Thickness Skin Graft (STSG) donor site.
- Conditions
- Wound Healing, Wound Infection, Pain, Pruritus
- Trial name
- NCT01769144
- Testing
- Acticoat Absorbent, BCT
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Kaohsiung Veterans General Hospital.
NPWT, Latissimus Dorsi Flap
Role of Negative Pressure Wound Therapy in Latissimus Dorsi Flap Donor Site Seroma Prevention
The use of NPWT as a post-operative dressing significantly reduces the incidence of seroma formation after harvesting LD flap.
- Conditions
- NPWT, Latissimus Dorsi Flap, Breast Reconstruction
- Trial name
- NCT02442401
- Testing
- The negative pressure wound therapy
- Volunteers
- 40 people
- Sponsor
- Chulalongkorn University
Lung Transplant Rejection
Longitudinal Study of Cell Free DNA in Lung Transplant
Lung transplant is a viable treatment strategy for many with end-stage lung diseases. Despite advances in both the surgical and medical management, lung transplant recipients experience episodes of allograft insult and injury…
- Trial name
- LoSt (NCT04234919)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Colorado, Denver
Blood Donors
Motivating Type O- Blood Donors to Return
This study develops a motivational interview and implementation intention intervention for blood donor retention and tests the efficacy of this new approach among first-time, Group O donors.
- Trial name
- NCT02274064
- Testing
- Motivational Interview and Implementation Intention
- Where
- United States
- Volunteers
- 598 people
- Sponsor
- Ohio University
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
End Stage Renal Disease
Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
The purpose of this study is to determine whether high dose IVIG and B cell depleting agents can be used effectively in highly sensitized wait-listed patients.
- Trial name
- NCT01502267
- Testing
- High dose IVIG and B cell depleting agents
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.